Solventum Corp (SOLV) is overvalued and West Pharmaceutical Services Inc (WST) is overvalued.
Both trade above our estimate of their intrinsic value. SOLV is the closer of the two: -73%, against -256% for WST.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $51.30; the price of $88.75 is 73% above that value, and 79% of that value comes from beyond year five.
Leak Score 59/100 on 3 of 12 signals
Discounting its cash flows at 10.4% (average of 3 methods) values the shares at $104.26; the price of $371.09 is 256% above that value, and 71% of that value comes from beyond year five.
Leak Score 61/100 on 10 of 12 signals
| Metric | SOLV | WST |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $88.75 | $371.09 |
| Intrinsic value | $51.30 | $104.26 |
| Margin of safety | -73% | -256% |
| Leak Score | 59/100 (3/12) | 61/100 (10/12) |
| Market cap | $15.1B | $26.1B |
| Revenue growth, 5 years | 0.5% | 7.4% |
| Operating margin | 8.5% | 22.0% |
| Net margin | 17.3% | 17.0% |
| Return on equity | 34.0% | 19.1% |
| Debt to equity | 1.10 | 0.11 |
| P/E | 10.8x | 47.4x |
| Forward P/E | 12.1x | 37.1x |
| P/B | 3.1x | 8.7x |
| Dividend yield | — | 0.2% |